Organon & Co (OGN) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.106x

Based on the latest financial reports, Organon & Co (OGN) has a cash flow conversion efficiency ratio of 0.106x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($107.00 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Organon & Co market cap and net worth for the company's overall valuation and market capitalisation.

Organon & Co - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Organon & Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Organon & Co Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Organon & Co ranked by their cash flow conversion efficiency. Explore Organon & Co earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Dolby Laboratories
NYSE:DLB
0.134x
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
0.144x
QL Resources Bhd
KLSE:7084
0.012x
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
-0.131x
Ottobock SE & Co. KGaA
XETRA:OBCK
0.133x
Axcelis Technologies Inc
NASDAQ:ACLS
0.017x
RUBIS
F:BYN
N/A
Krones AG
XETRA:KRN
0.010x

Annual Cash Flow Conversion Efficiency for Organon & Co (2018–2025)

The table below shows the annual cash flow conversion efficiency of Organon & Co from 2018 to 2025. View OGN share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $752.00 Million $700.00 Million 0.931x -53.21%
2024-12-31 $472.00 Million $939.00 Million 1.989x +117.43%
2023-12-31 $-70.00 Million $799.00 Million -11.414x -1086.66%
2022-12-31 $-892.00 Million $858.00 Million -0.962x +40.99%
2021-12-31 $-1.51 Billion $2.46 Billion -1.630x -508.87%
2020-12-31 $5.49 Billion $2.19 Billion 0.399x +1.36%
2019-12-31 $7.04 Billion $2.77 Billion 0.393x -32.28%
2018-12-31 $6.35 Billion $3.69 Billion 0.581x --

About Organon & Co

NYSE:OGN USA Drug Manufacturers - General
Market Cap
$3.60 Billion
Market Cap Rank
#4446 Global
#1519 in USA
Share Price
$13.70
Change (1 day)
+0.15%
52-Week Range
$5.70 - $13.78
All Time High
$33.87
About

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more